SCM
ANIK icon

Stonepine Capital Management’s Anika Therapeutics ANIK Stock Holding History

Stonepine Capital Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-190,590
Closed -$2.02M – 60
2025
Q2 		$2.02M Sell
190,590
-16,049
-8% -$203K 1.98% 15
2025
Q1 		$3.26M Sell
206,639
-31,583
-13% -$525K 3.17% 8
2024
Q4 		$3.92M Buy
238,222
+48,914
+26% +$965K 3.17% 9
2024
Q3 		$4.68M Buy
189,308
+23,911
+14% +$620K 2.95% 9
2024
Q2 		$4.19M Buy
165,397
+104,448
+171% +$2.71M 3.82% 7
2024
Q1 		$1.55M Buy
+60,949
New +$1.47M 1.23% 12

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Stonepine Capital Management's ANIK Position: Q3 2025 in Review

Stonepine Capital Management sold out of Anika Therapeutics (ANIK) in Q3 2025, closing a stake of 190,590 shares — an estimated $2.02M sold.

Stonepine Capital Management first reported a position in ANIK in Q1 2024 and held it in 6 quarters. The position peaked at $4.68M in Q3 2024. 117 funds tracked by Wall St. Rank hold ANIK as of Q3 2025.

  • Stonepine Capital Management reported no remaining Anika Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Stonepine Capital Management sold 190,590 Anika Therapeutics shares in Q3 2025, an estimated $2.02M.
  • Stonepine Capital Management first reported a position in Anika Therapeutics in Q1 2024 and held it in 6 quarters.
  • Stonepine Capital Management's Anika Therapeutics position peaked at $4.68M in Q3 2024.
  • 117 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2025.

Based on Stonepine Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.